Aytu BioPharma, Inc. is a pharmaceutical company focused on commercializing novel therapeutics. The Company's business is focused on its prescription pharmaceutical products sold primarily through third party wholesalers and pharmacies and which primarily consists of two product portfolios. The first consists of two products for the treatment of ADHD: Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (Adzenys) and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets. The second consists primarily of Karbinal ER (carbinoxamine maleate extended-release oral suspension), an extended-release first-generation antihistamine suspension containing carbinoxamine indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency.
Código de la empresaAYTU
Nombre de la empresaAytu Biopharma Inc
Fecha de salida a bolsaOct 20, 2017
Fundada en2015
Director ejecutivoMr. Joshua R. (Josh) Disbrow
Número de empleados99
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 20
Dirección7900 E. Union Avenue
CiudadDENVER
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal80237
Teléfono17204376580
Sitio Webhttps://aytubio.com/
Código de la empresaAYTU
Fecha de salida a bolsaOct 20, 2017
Fundada en2015
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos